GSK 586529
Alternative Names: 586529; GSK586529Latest Information Update: 01 Aug 2023
At a glance
- Originator GlaxoSmithKline; Neurocrine Biosciences
- Developer GlaxoSmithKline
- Class Antidepressants; Anxiolytics; Small molecules
- Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Depressive disorders
Most Recent Events
- 26 Jun 2012 Discontinued - Phase-I for Anxiety disorders in USA (PO)
- 26 Jun 2012 Discontinued - Phase-I for Depressive disorders in USA (PO)
- 05 Feb 2008 Phase-I clinical trials in Anxiety disorders in USA (PO)